Conditions: Age-related Macular Degeneration
Keywords: age-related macular degeneration (AMD) choroidal neovascularization membrane(CNVM) ranibizumab anti-vascular endothelial growth factor electrophysiology electroretinography
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 25
Healthy volunteers: no

Brief summary:
Age-related macular degeneration, a leading cause of blindness, is caused by an abnormal growth of the vessels beneath the retina. Ranibizumab (Lucentis) is a new drug that inhibits the growth of new vessels and has recently been approved by FDA for treating this condition. This study is carried out to evaluate the changes in retinal function after an injection of ranibizumab.

Detailed description:
The functional changes of the retina can be recorded by an electroretinography (ERG).

Arms:

Interventions: intervention 1: ranibizumab
Intervention descriptions: intervention 1: A single dose of 0.5 mg ranibizumab injected intravitreally.

Protocol document: